Glenmark receives ANDA approval for Aspirin and generic version of Aggrenox® Capsules
May 27, 2019 | Monday | News
Glenmark’s current portfolio consists of 155 products authorized for distribution in the U.S. marketplace
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, a generic version of Aggrenox® Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending March 2019, the Aggrenox® Capsules, 25 mg/200 mg market2 achieved annual sales of approximately $165.6 million.
Glenmark’s current portfolio consists of 155 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the U.S. FDA.
